Loading...
Loading...
- Since Quest Diagnostics Incorporated DGX reported its Q2 FY21 financial results, COVID-19 molecular testing volumes were stronger than anticipated through the end of August.
- Related Content: Quest Q2 Earnings Ahead Of Expectation On Recovery Of Non-COVID Business, Issues Mixed FY21 Guidance.
- The demand is expected to continue to be stronger than anticipated because of the surge of the Delta variant. The low end of the Company's outlook now assumes average COVID-19 volumes of at least 40,000 molecular tests per day for the second half of the year.
- Organic testing volumes in the Company's base business remain consistent with its previous outlook.
- Quest Diagnostics expects FY21 sales of $9.84 billion - $10.09 billion, compared to earlier guidance of $9.54 billion- $9.79 billion, compared to the Wall Street sales estimate of $9.79 billion.
- It expects an adjusted EPS of $11.65 - $12.35 (consensus $11.38), compared to prior estimate of $10.65 - $11.35.
- Quest expects an operating cash flow of at least $2.0 billion.
- Also Read: Vapotherm Raises Annual Sales Outlook Amid Surge In COVID-19 Cases.
- Price Action: DGX stock is up 1.30% at $160.06 during the market session on the last check Thursday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in